Sign in
CompletedPhase 3

Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in Households

Key facts

Who runs it
Hoffmann-La Roche
Where
Atlanta, Birmingham, Butte, Canoga Park, Charlotte, Chattanooga, Cincinnati, Dallas, Denison, Denver, Fort Lauderdale, Greer, Houston, Idaho Falls, Jackson, Kingwood, Kissimmee, Las Vegas, Long Beach, Los Angeles, McAllen, Miami, Mishawaka, Missoula, Morganton, Pelham, Philadelphia, Phoenix, Riverside, San Antonio, San Diego, Scottdale, Smithfield, South Miami, and St Louis, United StatesSee the 42 sitesAlso in 15 other countries, 99 sites
Status
Completed
Phase
Phase 3
People taking part
4,138 people enrolled
Started
10 Oct 2019
Ended
10 May 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Baloxavir Marboxil
  • Placebo
Record updated
4 July 2025

Who can take part

Age
5 years to 64 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 40 criteriaShow less

Who can take part

  • Index Patients (IPs):
  • Able to comply with the study protocol per investigator judgment
  • Diagnosed with acute influenza infection by investigator
  • Polymerase chain reaction [PCR] (+) or Rapid Influenza Diagnostic Test [RIDT] (+) for influenza A/B based on cobas® SARS-CoV-2 and influenza A/B or other point-of-care / local laboratory results
  • PCR (-) or antigen test (-) for SARS-CoV-2 based on cobas® SARS-CoV-2 and Influenza A/B test or other point-of-care / local laboratory result
  • Presence of (a) fever (>=38.0 °C per tympanic or rectal thermometer; >=37.5 °C per axillary, oral or forehead/temporal thermometer) or (b) any influenza symptoms (cough, sore throat, nasal congestion, headache, feverishness or chills, muscle or joint pain, fatigue)
  • The time interval between the onset of fever or influenza symptoms and the pre-dose examinations is 48 hours or less
  • IP lives in a household where: (1) No HHC is known to have been diagnosed with influenza or SARS-CoV-2 infection by a healthcare professional (HCP) in the past 4 weeks; (2) All HHCs are expected to meet the key HHC inclusion criteria; (3) >=1 HHCs are expected to participate in the full study who have not received the influenza vaccine within 6 months prior to screening
  • Women of childbearing potential: Agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures specified in the protocol; All HHCs (Part 1):
  • PCR (-) or RIDT (-) based on cobas® SARS-CoV-2 and influenza A/B or other local point-of-care / local laboratory result
  • PCR (-) or antigen test (-) for SARS-CoV-2 based on cobas® SARS-CoV-2 and Influenza A/B or other POC / local laboratory result
  • HHC lives with no HHC who will be present in the home at any time during the study and who meets any HHC exclusion criteria
  • HHC lives with no HHC who does not meet HHC inclusion criteria (part 1)
  • HHC lives in a household where ≥1 HHCs meet all of the following: Start screening within 24 hours after IP randomization; Have NOT received the influenza vaccine within 6 months prior to screening; and Fulfill full study HHC inclusion criteria part 2; Full study HHCs (part 2) intended for full study must meet the following additional criteria for study entry:
  • Agree to participate in the full study
  • Able to comply with the study protocol per investigator judgment
  • No influenza symptoms within 7 days prior to screening. Alternatively, mild symptoms are permissible if determined by the investigator to be due to a preexisting condition
  • Temperature <38.0 °C (tympanic)
  • Will reside in the index patient's house for at least 7 of the next 9 days and will be present for scheduled study visits
  • Willing and able to measure and record temperature, or have another household member perform the task on his or her behalf. Furthermore, a responsible adult will assume responsibility to oversee or perform this task on behalf of minors
  • In the 6 months prior to screening: a) Has not been diagnosed with influenza by a healthcare professional b) Has not received BXM, peramivir, laninamivir, oseltamivir, zanamivir, rimantadine, umifenovir, favipiravir or amantadine
  • Does not have a moderate or worse active infections OR infections requiring systemic (e.g., oral or intravenous) or otherwise internally administered (e.g., inhaled, intrathecal) antibiotic/antiviral/antifungal therapy, (topical therapies for mild external infections allowed)

Who cannot take part

  • IPs with concurrent (non-influenza) infections requiring systemic antimicrobial and/or antiviral therapy at the pre-dose examinations
  • IPs who have received baloxavir marboxil, peramivir, laninamivir, oseltamivir, zanamivir, rimantadine, umifenovir, favipiravir or amantadine, or an investigational drug, within 30 days or 5 drug-elimination half-lives, whichever is longer, prior to screening
  • IPs who have received an investigational monoclonal antibody for a viral disease in the last year
  • IP previously included in the study
  • Who have received an investigational therapy within the 30 days or 5 drug elimination half-lives, whichever is longer, prior to screening
  • HHC previously included in the study
  • IPs with severe influenza virus infection requiring inpatient treatment
  • Known hypersensitivity to baloxavir marboxil or the drug product excipients
  • Diagnosed with influenza or SARS-CoV-2 infection by a healthcare professional in the past 4 weeks
  • IP is ≥12 years old and unable to swallow tablets (not applicable to IPs 5 to 11 year olds who will receive oral suspension)
  • Less than 2 years old
  • IPs:
  • IPs judged by the investigator to be at high risk for complications of influenza
  • Women who are breastfeeding or have a positive pregnancy test in the pre-dose examinations
  • IP lives with an HHC who, based on available information, meets the HHC exclusion criteria; HHC:
  • Pregnant or within 2 weeks post-partum at screening
  • Immunocompromised
  • HHC who plans to arrive home after 24 hours post IP randomization to Day 9 and is not willing to be consented as soon as possible upon arrival

Where in United States

Also in 15 other countries, 99 sites

  • Agile Clinical Research TrialsAtlanta, United States
  • Cahaba Research IncBirmingham, United States
  • Mercury Street Medical GroupButte, United States
  • Hope Clinical ResearchCanoga Park, United States
  • Onsite Clinical Solutions, LLCCharlotte, United States
  • AFC Urgent Care-GunbarrellChattanooga, United States
  • Hometown Urgent Care and Occupational Health - SpringdaleCincinnati, United States
  • City Doc Urgent Care-Dallas/Ft. WorthDallas, United States
  • Southwest Family Medicine AssociatesDallas, United States
  • Premier Pulmonary Critical Care and Sleep MedicineDenison, United States
  • Cherry Creek Family PracticeDenver, United States
  • Proactive Clinical Research,LLCFort Lauderdale, United States
  • Jedda Enterprises dba Galen Clinical ResearchGreer, United States
  • Fairway Medical ClinicHouston, United States
  • Mercury Clinical ResearchHouston, United States
  • Pioneer Research SolutionsHouston, United States
  • Vilo Research GroupHouston, United States
  • Clinical Research PrimeIdaho Falls, United States
  • Helios Clinical Research, Inc (former Ventavia Research Group)Jackson, United States
  • Frontier Clinical ResearchKingwood, United States
  • Helios Clinical Research, Inc (former Ventavia Research Group)Kissimmee, United States
  • Accent Clinical TrialsLas Vegas, United States
  • Excel Clinical ResearchLas Vegas, United States
  • Long Beach Clinical TrialsLong Beach, United States
  • Downtown LA Research CenterLos Angeles, United States
  • Family Practice CenterMcAllen, United States
  • Cordova Research Institute, LLCMiami, United States
  • Research Institute of South Florida, Inc.Miami, United States
  • South Florida Research Center, Inc.Miami, United States
  • Mishawaka Osteopathic ClinicMishawaka, United States
  • Montana Medical Research LLCMissoula, United States
  • Burke Primary CareMorganton, United States
  • Cahaba Research, Inc.Pelham, United States
  • Tristar Clinical InvestigationsPhiladelphia, United States
  • Precision TrialsPhoenix, United States
  • Probe Clinical ResearchRiverside, United States
  • Sun Research InstituteSan Antonio, United States
  • MD Strategies Research CentersSan Diego, United States
  • Frontier Clinical ResearchScottdale, United States
  • Frontier Clinical ResearchSmithfield, United States
  • Kendall South Medical Center Inc.South Miami, United States
  • Washington University School of MedicineSt Louis, United States

About the trial

What the trial wants to find out

Otherwise healthy index patients (IP) are randomized to either baloxavir marboxil or placebo if their influenza symptoms onset was within 48 hours of screening. Their households are enrolled within 24 hours of randomization if at least 1 household contacts (HHC) have not received influenza vaccine within 6 months of screening and if all HHC screen negative for influenza infection. The main endpoints are assessed based on multiple respiratory swabs, obtained from both IP and HHC up to 9 (+/-1) days post IP randomization, and through the assessment of symptoms.

The 2 groups in the trial

  • Baloxavir MarboxilTreatment being tested

    Participants who are IPs will receive a single oral dose of baloxavir marboxil. HHCs of the IPs will not receive study medication.

  • PlaceboPlacebo, for comparison

    Participants who are IPs will receive a single oral dose of placebo. HHCs of the IPs will not receive study medication.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase IIIB, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Clinical Efficacy Study of Baloxavir Marboxil for the Reduction of Direct Transmission of Influenza From Otherwise Healthy Patients to Household Contacts
Publications
Record updated
4 July 2025